|
DE19624659A1
(de)
*
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
DE19756236A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
PT1131291E
(pt)
*
|
1998-11-17 |
2005-01-31 |
Hoffmann La Roche |
Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
US6432432B1
(en)
|
1999-03-05 |
2002-08-13 |
Arch Chemicals, Inc. |
Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
|
|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
CO5370679A1
(es)
|
1999-06-01 |
2004-02-27 |
Smithkline Beecham Corp |
Inhibidores fab 1
|
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
AR025976A1
(es)
|
1999-10-08 |
2002-12-26 |
Affinium Pharm Inc |
Inhibidores de fab i.
|
|
CA2444597A1
(en)
|
2001-04-06 |
2002-10-06 |
Affinium Pharmaceuticals, Inc. |
Fab i inhibitors
|
|
FR2823975B1
(fr)
*
|
2001-04-27 |
2003-05-30 |
Sanofi Synthelabo |
Nouvelle utilisation de pyridoindolone
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
CN102558155A
(zh)
|
2003-01-14 |
2012-07-11 |
阿伦纳药品公司 |
作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
|
US20110045065A1
(en)
*
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
US8067457B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
EP2687533B1
(en)
|
2006-07-20 |
2017-07-19 |
Debiopharm International SA |
Acrylamide derivatives as FAB I inhibitors
|
|
WO2008026018A1
(en)
|
2006-09-01 |
2008-03-06 |
Topotarget Switzerland Sa |
New method for the treatment of inflammatory diseases
|
|
US8263613B2
(en)
|
2007-02-16 |
2012-09-11 |
Affinium Pharmaceuticals, Inc. |
Salts, prodrugs and polymorphs of fab I inhibitors
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
MX2010014310A
(es)
|
2008-06-24 |
2011-02-15 |
Topotarget As |
Derivados de acido escuarico como inhibidores de la nicotinamida.
|
|
CN102186822A
(zh)
|
2008-08-29 |
2011-09-14 |
顶标公司 |
新脲和硫脲衍生物
|
|
WO2010130178A1
(zh)
*
|
2009-05-12 |
2010-11-18 |
Sun Shuping |
丙烯酰胺类衍生物及其制备药物的用途
|
|
EP2453883A1
(en)
|
2009-07-17 |
2012-05-23 |
Topo Target A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
JP6038792B2
(ja)
|
2010-09-03 |
2016-12-07 |
フォーマ ティーエム， エルエルシー． |
癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
|
|
WO2012031197A1
(en)
|
2010-09-03 |
2012-03-08 |
Forma Therapeutics, Inc. |
Novel compounds and compositions for the inhibition of nampt
|
|
RU2593759C2
(ru)
|
2010-09-03 |
2016-08-10 |
ФОРМА ТиЭм, ЭлЭлСИ |
Гуанидиновые соединения и композиции для ингибирования nampt
|
|
MX2013003184A
(es)
|
2010-09-22 |
2013-06-07 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
|
|
US8877934B2
(en)
*
|
2010-09-29 |
2014-11-04 |
Intervet Inc. |
N-heteroaryl compounds
|
|
MX2013005454A
(es)
|
2010-11-15 |
2013-06-24 |
Abbvie Inc |
Inhibidores de nampt y rock.
|
|
WO2012067963A1
(en)
|
2010-11-15 |
2012-05-24 |
Abbott Laboratories |
Nampt inhibitors
|
|
CA2834746A1
(en)
*
|
2011-05-04 |
2012-11-08 |
Forma Tm, Llc |
Novel compounds and compositions for the inhibition of nampt
|
|
US9555039B2
(en)
*
|
2011-05-09 |
2017-01-31 |
Forma Tm, Llc. |
Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
|
|
EP2736887B1
(en)
|
2011-07-29 |
2017-10-18 |
Karyopharm Therapeutics, Inc. |
Hydrazide containing nuclear transport modulators and uses thereof
|
|
IN2014DN09434A
(enExample)
|
2012-05-09 |
2015-07-17 |
Karyopharm Therapeutics Inc |
|
|
WO2013170113A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
AR091023A1
(es)
|
2012-05-11 |
2014-12-30 |
Abbvie Inc |
Inhibidores del nampt
|
|
MX2014013758A
(es)
|
2012-05-11 |
2015-02-05 |
Abbvie Inc |
Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
|
|
AU2013259344A1
(en)
|
2012-05-11 |
2014-11-13 |
Abbvie Inc. |
Nampt inhibitors
|
|
SMT201900411T1
(it)
|
2012-06-19 |
2019-09-09 |
Debiopharm Int Sa |
Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
|
|
HK1215579A1
(zh)
|
2012-11-29 |
2016-09-02 |
Karyopharm Therapeutics, Inc. |
被取代的2，3-二氫苯並呋喃基化合物和其用途
|
|
WO2014144772A1
(en)
|
2013-03-15 |
2014-09-18 |
Karyopharm Therapeutics Inc. |
Methods of promoting wound healing using crm1 inhibitors
|
|
CN110386919B
(zh)
|
2013-06-21 |
2023-07-14 |
卡尔约药物治疗公司 |
核转运调节剂及其用途
|
|
CN108440515B
(zh)
*
|
2013-07-03 |
2022-05-03 |
卡尔约药物治疗公司 |
取代的苯并呋喃基和苯并噁唑基化合物及其用途
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
CA2921532A1
(en)
*
|
2013-10-09 |
2015-04-16 |
Eli Lilly And Company |
Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
|
|
EP3172205A1
(en)
|
2014-07-23 |
2017-05-31 |
Aurigene Discovery Technologies Limited |
4,5-dihydroisoxazole derivatives as nampt inhibitors
|
|
CN111484483B
(zh)
|
2014-08-15 |
2023-05-26 |
卡尔约药物治疗公司 |
赛灵克斯的多晶型物
|
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
CN104447483B
(zh)
*
|
2015-01-13 |
2016-07-27 |
佛山市赛维斯医药科技有限公司 |
含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
|
|
CN104447486B
(zh)
*
|
2015-01-13 |
2016-06-01 |
佛山市赛维斯医药科技有限公司 |
二烯氟代金刚烷类化合物、其制备方法和用途
|
|
CN104447484B
(zh)
*
|
2015-01-13 |
2016-06-08 |
佛山市赛维斯医药科技有限公司 |
含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
|
|
PL3310760T3
(pl)
|
2015-06-22 |
2023-03-06 |
Arena Pharmaceuticals, Inc. |
Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
|
|
CN108137563A
(zh)
|
2015-08-18 |
2018-06-08 |
卡尔约药物治疗公司 |
用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
|
|
TWI721016B
(zh)
*
|
2015-09-15 |
2021-03-11 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
US10526295B2
(en)
|
2015-12-31 |
2020-01-07 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
EP3397634A1
(en)
|
2015-12-31 |
2018-11-07 |
Karyopharm Therapeutics, Inc. |
Nuclear transport modulators and uses thereof
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
BR122023021456A2
(pt)
|
2016-02-26 |
2024-02-20 |
Debiopharm International S.A. |
Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
|
|
EP3279192A1
(en)
|
2016-08-05 |
2018-02-07 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Piperidine derivatives for use in the treatment of pancreatic cancer
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
US11602530B2
(en)
|
2016-11-28 |
2023-03-14 |
Biogen Ma Inc. |
CRM1 inhibitors for treating epilepsy
|
|
CN107827897A
(zh)
*
|
2017-10-23 |
2018-03-23 |
青岛大学 |
一种手性七元螺环吲哚酮类化合物的合成方法
|
|
WO2019149637A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
WO2019213570A1
(en)
|
2018-05-04 |
2019-11-07 |
Remedy Plan, Inc. |
Cancer treatments targeting cancer stem cells
|
|
CN108558840B
(zh)
*
|
2018-06-04 |
2020-11-06 |
上海交通大学 |
水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
|
|
AU2019280822A1
(en)
|
2018-06-06 |
2021-01-07 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
FI3923914T3
(fi)
|
2019-02-14 |
2023-04-27 |
Debiopharm Int Sa |
Afabisiiniformulaatio, menetelmä sen valmistamiseksi
|
|
MA56184A
(fr)
|
2019-06-14 |
2022-04-20 |
Debiopharm Int Sa |
Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
KR20220110744A
(ko)
|
2019-11-06 |
2022-08-09 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
JP2024518089A
(ja)
|
2021-05-13 |
2024-04-24 |
リメディー プラン，インコーポレーテッド |
Ｎａｍｐｔ阻害剤とその使用
|